This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Allergan Doesn't Accept Ackman's $600 Million Gift

Stocks in this article: AGN VRX

Updated from 9:01 a.m. ET to include Valeant statement, analyst comments

NEW YORK (TheStreet) -- Allergan (AGN) has decided not to engage with Pershing Square's Bill Ackman and Valeant Pharmaceuticals (VRX) just two weeks after the hedge funder decided to fork over $600 million to investors as part of his takeover effort.

>>Read More: Pershing Square and Valeant's Allergan Deal a Watershed

The botox-treatment specialist said on Tuesday its board has unanimously rejected Ackman and Valeant's takeover offer, which included 0.83 of Valeant common shares, $72.00 in cash per share of common stock and a contingent value right related to DARPin sales.

"Valeant's revised proposal substantially undervalues Allergan, creates significant risks and uncertainties for Allergan's stockholders and does not reflect the Company's financial strength, future revenue and earnings growth or industry-leading R&D," David E.I. Pyott, Allergan's chairman of the board and chief executive officer, said in a Tuesday statement.

Pyott also said he believes investors are confident in Allergan's growth prospects and are willing to continue investing in the company as a standalone. On May 12, Allergan forecast it would generate double-digit sales growth and 20% compound earnings-per-share growth over the next five years, in addition to approximately $14 billion in additional free cash flow during that time span.

"The Board is confident that the Company will create significantly more value for stockholders than Valeant's proposal. We look forward to updating stockholders on or around the time of our second quarter earnings announcement," Pyott concluded.

In rejecting Ackman and Valeant's latest offer, Allergan reiterated its belief that Valeant's business model is unsustainable, has low organic growth, is over-leveraged, and relies too heavily upon acquisitions for growth.

Allergan shares were little changed at $163.80, while Valeant shares were falling over 1% to $124.99. Year-to-date, Allergan has risen over 47%, mostly as a result of Ackman and Valeant's takeover interest.

"Rather than discussing the benefits of the proposed combination with Valeant, Allergan's Board continues to throw out innacurate and misleading statements about Valeant and is recycling the same unsupported arguments about Valeant that have already been addressed, leaving us no choice but to take our offer directly to shareholders," Laurie Little, Valeant's VP of Investor Relations, said in an e-mailed statement.

Ackman's Smart Move Rebuffed

Ackman's decision in late May to give $600 million to Allergan shareholders in a revised proposal with Valeant to buy the company looked like a smart move. It allowed Valeant to effectively improve on its takeover offer and could have been enough to bring all parties to the negotiating table.

It also underscored Ackman's confidence in the strategic merit of Valeant's play for Allergan.

As part of a revised offer, Ackman agreed to taking only Valeant stock for Pershing's 9.7% holding of Allergan shares, in addition to a lower price in the cash and stock deal. That offer meant Pershing Square wouldn't receive a dime of cash for a significant time after the prospective deal closes.

Pershing also wouldn't benefit from Allergan's rising takeover price if a sweepstakes emerged.

Were a deal to close under the terms of Ackman and Valeant's latest offer, Allergan shareholders would receive $179.25 a share in cash and stock, with $72 a share of the consideration coming in cash and the rest in Valeant stock. Ackman, by contrast, would only receive $158.50 for his Allergan shares and all in stock.

A Line in the Sand?

Perhaps now that Allergan's board has formally rejected what appeared to be Ackman and Valeant's best offer, it will be time for investors to decide whom to support.

Ackman has made no secret he is willing to take his offer directly to Allergan shareholders and the company's strong stock gains in 2014 present tangible proof that there is value in it. Allergan, by contrast, appears confident that investors are on the company's side and won't be enticed by Ackman and Valeant's cash and stock deal.

Analysts at Buckingham Research Group said in a Tuesday report Allergan could look to M&A or share repurchases to support its stock price and provide a real alternative to Valeant's offer. Similarly, Wells Fargo analysts pointed to Allergan's forthcoming guidance on a second quarter earnings and insight into the value of assets in the company's DARPin pipeline call as a possible positive for the company's shares.

What is clear is that after multiple bids, hour-long conference calls and a flurry of press on both sides of a deal, this takeover effort is just heating up.

Wachtell Sees Threat in Ackman's Activism

Chane Happened At Air Products Before Ackman Entered

Platform Specialty Products Emerges As a Dealmaker

-- Written by Antoine Gara in New York.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs